RAD23B

Across TCGA pan-cancer cohorts, RAD23B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RAD23B data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RAD23B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAD23B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, UCEC, and LUAD are the cancer types where RAD23B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.928	0.105	.006	30	view →
UCEC	DFS	Quartile	All	1.000	0.790	.013	4	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RAD23B–CCRCC (DFS)

Open the CCRCC breakdown →